Immune System Stimulation by Oncolytic Rodent Protoparvoviruses

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2019 May 8

PMID 31060205

Citations 10

Authors

Assia Angelova

Jean Rommelaere

Affiliations

Soon will be listed here.

Abstract

Rodent protoparvoviruses (PVs), parvovirus H-1 (H-1PV) in particular, are naturally endowed with oncolytic properties. While being historically described as agents that selectively replicate in and kill cancer cells, recent yet growing evidence demonstrates that these viruses are able to reverse tumor-driven immune suppression through induction of immunogenic tumor cell death, and the establishment of antitumorigenic, proinflammatory milieu within the tumor microenvironment. This review summarizes the most important preclinical proofs of the interplay and the cooperation between PVs and the host immune system. The molecular mechanisms of PV-induced immunostimulation are also discussed. Furthermore, initial encouraging in-human observations from clinical trials and compassionate virus uses are presented, and speak in favor of further H-1PV clinical development as partner drug in combined immunotherapeutic protocols.

Citing Articles

Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.

Salvato I, Marchini A Cancers (Basel). 2024; 16(7).

PMID: 38610954 PMC: 11010873. DOI: 10.3390/cancers16071276.

The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics.

Angelova A, Rommelaere J, Ungerechts G Pathogens. 2024; 13(3).

PMID: 38535528 PMC: 10975429. DOI: 10.3390/pathogens13030184.

Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer.

Luo W, Wang Y, Zhang T Cancer Cell Int. 2022; 22(1):160.

PMID: 35443724 PMC: 9022249. DOI: 10.1186/s12935-022-02583-1.

Oncolytic viruses for triple negative breast cancer and beyond.

Jin S, Wang Q, Wu H, Pang D, Xu S Biomark Res. 2021; 9(1):71.

PMID: 34563270 PMC: 8466906. DOI: 10.1186/s40364-021-00318-4.

Canine Parvovirus and Its Non-Structural Gene 1 as Oncolytic Agents: Mechanism of Action and Induction of Anti-Tumor Immune Response.

Arora R, Malla W, Tyagi A, Mahajan S, Sajjanar B, Tiwari A Front Oncol. 2021; 11:648873.

PMID: 34012915 PMC: 8127782. DOI: 10.3389/fonc.2021.648873.

References

Angelova A, Barf M, Geletneky K, Unterberg A, Rommelaere J . Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity. Viruses. 2017; 9(12). PMC: 5744156. DOI: 10.3390/v9120382. View

Marchini A, Bonifati S, Scott E, Angelova A, Rommelaere J . Oncolytic parvoviruses: from basic virology to clinical applications. Virol J. 2015; 12:6. PMC: 4323056. DOI: 10.1186/s12985-014-0223-y. View

Geletneky K, Nuesch J, Angelova A, Kiprianova I, Rommelaere J . Double-faceted mechanism of parvoviral oncosuppression. Curr Opin Virol. 2015; 13:17-24. DOI: 10.1016/j.coviro.2015.03.008. View

Raykov Z, Grekova S, Horlein R, Leuchs B, Giese T, Giese N . TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells. PLoS One. 2013; 8(1):e55086. PMC: 3558501. DOI: 10.1371/journal.pone.0055086. View

Rommelaere J, Geletneky K, Angelova A, Daeffler L, Dinsart C, Kiprianova I . Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. 2010; 21(2-3):185-95. DOI: 10.1016/j.cytogfr.2010.02.011. View

Ventoso I, Berlanga J, Almendral J . Translation control by protein kinase R restricts minute virus of mice infection: role in parvovirus oncolysis. J Virol. 2010; 84(10):5043-51. PMC: 2863853. DOI: 10.1128/JVI.02188-09. View

Bhat R, Rommelaere J . NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer. 2013; 13:367. PMC: 3733944. DOI: 10.1186/1471-2407-13-367. View

Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M . Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer. 2011; 11:464. PMC: 3234202. DOI: 10.1186/1471-2407-11-464. View

Mattei L, Cotmore S, Tattersall P, Iwasaki A . Parvovirus evades interferon-dependent viral control in primary mouse embryonic fibroblasts. Virology. 2013; 442(1):20-7. PMC: 3767977. DOI: 10.1016/j.virol.2013.03.020. View

10.

Ball-Goodrich L, Paturzo F, Johnson E, Steger K, Jacoby R . Immune responses to the major capsid protein during parvovirus infection of rats. J Virol. 2002; 76(19):10044-9. PMC: 136518. DOI: 10.1128/jvi.76.19.10044-10049.2002. View

11.

Mattei L, Cotmore S, Li L, Tattersall P, Iwasaki A . Toll-like receptor 9 in plasmacytoid dendritic cells fails to detect parvoviruses. J Virol. 2013; 87(6):3605-8. PMC: 3592163. DOI: 10.1128/JVI.03155-12. View

12.

Chung Y, Jun H, Son M, Bao M, Bae H, Kang Y . Cellular and molecular mechanism for Kilham rat virus-induced autoimmune diabetes in DR-BB rats. J Immunol. 2000; 165(5):2866-76. DOI: 10.4049/jimmunol.165.5.2866. View

13.

Angelova A, Geletneky K, Nuesch J, Rommelaere J . Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients. Front Bioeng Biotechnol. 2015; 3:55. PMC: 4406089. DOI: 10.3389/fbioe.2015.00055. View

14.

Elamin Y, Rafee S, Toomey S, Hennessy B . Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron. 2014; 8(1):15-21. PMC: 4449343. DOI: 10.1007/s12307-014-0160-8. View

15.

Abschuetz A, Kehl T, Geibig R, Leuchs B, Rommelaere J, Regnier-Vigouroux A . Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells. Cell Tissue Res. 2006; 325(3):423-36. DOI: 10.1007/s00441-006-0199-z. View

16.

Nuesch J, Lacroix J, Marchini A, Rommelaere J . Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res. 2012; 18(13):3516-23. DOI: 10.1158/1078-0432.CCR-11-2325. View

17.

Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jager D . A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. BMC Cancer. 2017; 17(1):576. PMC: 5574242. DOI: 10.1186/s12885-017-3604-y. View

18.

Giese N, Raykov Z, DeMartino L, Vecchi A, Sozzani S, Dinsart C . Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther. 2002; 9(5):432-42. DOI: 10.1038/sj.cgt.7700457. View

19.

Grekova S, Aprahamian M, Daeffler L, Leuchs B, Angelova A, Giese T . Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biol Ther. 2011; 12(10):888-95. PMC: 3280904. DOI: 10.4161/cbt.12.10.17678. View

20.

Bretscher C, Marchini A . H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. Viruses. 2019; 11(6). PMC: 6630270. DOI: 10.3390/v11060562. View